PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Both yoy net incomes decline, with CRVO at -315.30%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
6.88%
D&A growth of 6.88% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Negative yoy SBC while CRVO is 74.11%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-183.61%
Negative yoy working capital usage while CRVO is 1024.48%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-219.11%
Negative yoy AP while CRVO is 21.37%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
200.00%
Growth well above CRVO's 290.99%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Both yoy CFO lines are negative, with CRVO at -267.61%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.33%
Debt repayment growth of 33.33% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-53.76%
Both yoy lines negative, with CRVO at -100.03%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.